Fighting Cancer and Infections with T Cell Therapy Wednesday, February 17, 2016 The quest to bring immunotherapy into widespread clinical use against cancer and infectious diseases has made great strides in recent years. For example, clinical trials of adoptive T cell therapy are yielding highly promising results. Visualizing a Parasite Crossing the Blood Brain Barrier Wednesday, February 17, 2016 An estimated 30 percent of the world’s population is chronically infected with the parasite Toxoplasma gondii. Novartis-Penn Center for Advanced Cellular Therapeutics Unveiled Wednesday, February 17, 2016 Research and development facility aims to expand progress in personalized cellular therapies for cancer.Leukemia’s Surroundings Key to its Growth Friday, February 12, 2016 Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.Immunovia, Lund University Collaborate Friday, February 12, 2016 Immunovia initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for SLE also known as “lupus”.Unique Mechanism for a High-Risk Leukemia Wednesday, February 10, 2016 Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.Food Triggers Creation of Regulatory T Cells Monday, February 08, 2016 IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.Mersana Therapeutics, Takeda Expand Partnership Monday, February 08, 2016 Mersana to receive $40 million upfront, $20 million upon IND clearance and up to $20 million in equity investment. Therapeutic Approach Gives Hope for Multiple Myeloma Monday, February 08, 2016 A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.